Cencora (COR) delivered mixed results in its recent earning calls despite some signs of growth. Among the standout updates, the company reported a surge in Q2 earnings and raised its
FY2025 EPS guidance to $15.70-$15.95 thanks to specialty growth. With a strong presence as the healthcare distributor and impressive future projections, it has been attracting growth investors. Several Wall Street analysts maintain positive stances, with
JPMorgan and
Citigroup both boosting their price targets on the stock. Although Cencora missed Q2 revenue expectations its role in the market remains strong. Despite some insider selling from Lon Greenberg, those who invested in Cencora five years ago have seen splendid returns.
Jim Cramer endorsed the stock, describing it as a “middleman money machine” and a “must-own” due to it seemingly always working. Cencora is not just focused on short-term returns; it announced technology acquisitions and investments, including a potential purchase of
OneOncology. Furthermore, the surge in the stock price of Cencora comes along with strong returns and increased price targets from various analysts. Nevertheless, with strong momentum and significant focus on long-term growth, Cencora looks well-positioned for future success.
Cencora COR News Analytics from Mon, 04 Nov 2024 08:00:00 GMT to Sat, 17 May 2025 08:04:35 GMT -
Rating 9
- Innovation 8
- Information 7
- Rumor 7
